APGE Furnishes Q2 2025 Results; Exhibit 99.1 and Exhibit 104 Provided

Rhea-AI Filing Summary

Apogee Therapeutics, Inc. furnished an earnings press release announcing its financial results for the quarter ended June 30, 2025. The press release is attached to this Current Report as Exhibit 99.1, and a Cover Page Interactive Data File is provided as Exhibit 104.

The filing states that the exhibit furnished under Item 2.02 is not deemed to be "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings. The registrant is Apogee Therapeutics, Inc., incorporated in Delaware, trading on the Nasdaq Global Market under the symbol APGE.

Positive

• Earnings press release furnished as Exhibit 99.1, making the company’s quarter-ended results publicly accessible.
• Cover Page Interactive Data File included as Exhibit 104, supporting structured data access.

Negative

• None.

Insights

Securities Analyst

TL;DR: Routine earnings press release furnished; no financial figures in the filing, so immediate market impact is unclear.

The company furnished an earnings press release for the quarter ended June 30, 2025 as Exhibit 99.1 and included an Inline XBRL cover page as Exhibit 104. The document explicitly states the exhibit is "furnished" and not "filed," limiting Section 18 liability and indicating this submission is primarily for disclosure rather than for incorporation into other filings. Because the filing contains no income statement, revenue, or guidance figures, investors and analysts must review Exhibit 99.1 itself for substantive financial information.

Corporate Governance Expert

TL;DR: Presentation of the earnings release as "furnished" is a standard disclosure practice; the filing itself contains no material financial details.

The Form 8-K documents the furnishing of an earnings press release and the provision of an interactive data cover page. The filing reiterates that the furnished exhibit is not "filed" under the Exchange Act, which clarifies the company’s legal exposure under Section 18. From a governance perspective, this is a routine disclosure step to ensure public availability of quarterly results while preserving the company’s filing boundaries; the filing by itself does not change corporate governance or financial commitments.

0001974640false00019746402025-08-112025-08-11

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 11, 2025

Apogee Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-41740	93-4958665
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
221 Crescent St., Bldg 17, Suite 102b
Waltham, Massachusetts				02453
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (650) 394-5230

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.00001 per share		APGE		The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On August 11, 2025, Apogee Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2025 (the “Earnings Press Release”).

A copy of the Earnings Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K (the “Form 8-K”) and is incorporated by reference herein. The exhibit furnished under Item 2.02 of this Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended (the “Securities Act”), regardless of any general incorporation language in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits. The following exhibits are being furnished herewith:

EXHIBIT INDEX

Exhibit No.		Description
99.1		Earnings Press Release, dated August 11, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			Apogee Therapeutics, Inc.
Date:	August 11, 2025	By:	/s/ Michael Henderson, M.D.
			Michael Henderson, M.D. Chief Executive Officer

FAQ

What did Apogee Therapeutics (APGE) disclose in this 8-K?

The company furnished an earnings press release for the quarter ended June 30, 2025 as Exhibit 99.1 and provided a Cover Page Interactive Data File as Exhibit 104.

Is the Earnings Press Release in Exhibit 99.1 considered "filed" with the SEC?

No. The filing explicitly states the exhibit furnished under Item 2.02 shall not be deemed to be "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings.

Which fiscal quarter does the press release cover for APGE?

The press release announces results for the quarter ended June 30, 2025.

On which exchange is Apogee Therapeutics listed and what is its ticker?

Apogee Therapeutics, Inc. is registered to trade on the Nasdaq Global Market under the symbol APGE.

Who signed the Form 8-K for Apogee Therapeutics?

The report is signed on behalf of the registrant by Michael Henderson, M.D., Chief Executive Officer.